H. Lee Moffitt Cancer Center and Research Institute: Myelodysplastic Syndromes trials

The registry lists 20 Myelodysplastic Syndromes studies with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 7Phase 2 14Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AMLCompletedNCT04620681Phase 1/2Results posted
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
• Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid NeoplasmsCompletedNCT03072043Phase 1/2Results posted
• Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCTCompletedNCT03018223Phase 1Results posted
• Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)CompletedNCT01842646Phase 2Results posted
• Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)CompletedNCT01822691Phase 2Results posted
• Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDSCompletedNCT01133275Phase 2Results posted
• Erlotinib Study for Myelodysplastic Syndrome (MDS)CompletedNCT00977548Phase 2Results posted
• Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)CompletedNCT00831766Phase 1/2Results posted
• Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell TransplantCompletedNCT00660400Not applicableResults posted
• Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow BlastsCompletedNCT00624585Not applicableResults posted
• Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)CompletedNCT00361140Phase 4Results posted
• Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN NeoplasmsActive, not recruitingNCT05732961Phase 2
• Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAActive, not recruitingNCT04798339Phase 1/2
• Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With ThrombocytopeniaTerminatedNCT01286038Phase 1
• Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)CompletedNCT00840931Phase 1
• Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow TransplantTerminatedNCT00005852Phase 2
• Bone Marrow Transplant in Treating Patients With Hematologic CancersCompletedNCT00005797Phase 2
• Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow TransplantationTerminatedNCT00005641Phase 2
• Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic DisordersCompletedNCT00005622Phase 2